Cost Estimation of Cardiovascular Disease Events in the US
- 1 August 2011
- journal article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 29 (8), 693-704
- https://doi.org/10.2165/11584620-000000000-00000
Abstract
Background: In this study, we developed cost prediction equations that facilitate estimation of the costs of various cardiovascular events for patients of specific demographic and clinical characteristics over varying time horizons. Methods: We used administrative claims data and generalized linear models to develop cost prediction equations for selected cardiovascular events, including myocardial infarction (MI), angina, strokes and revascularization procedures. Separate equations were estimated for patients with events and for their propensity score-matched controls. Attributable costs were estimated on a monthly basis for the first 36 months after each event and annually thereafter, with differences in survival between cases and controls factored into the longitudinal cost calculations. The regression models were used to estimate event costs ($US, year 2007 values) for the average patient in each event group, over various time periods ranging from 1 month to lifetime. Results: When the equations are run for the average patient in each event group, attributable costs of each event in the acute phase (i.e. first 3 years) are substantial (e.g. MI $US73 300; hospitalization for angina $US36 000; nonfatal haemorrhagic stroke $US71 600). Furthermore, for most events, cumulative costs remain substantially higher among cases than among controls over the remaining lifetime of the patients. Conclusions: This study provides updated estimates of medical care costs of cardiovascular events among a managed care population over various time horizons. Results suggest that the economic burden of cardiovascular disease is substantial, both in the acute phase as well as over the longer term.Keywords
This publication has 26 references indexed in Scilit:
- Costs of heart disease and risk behaviour: Implications for expenditure on preventionScandinavian Journal of Public Health, 2008
- Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets studyThe European Journal of Health Economics, 2008
- An Economic Evaluation of Atorvastatin for Primary Prevention of??Cardiovascular Events in Type??2??DiabetesPharmacoEconomics, 2008
- Cost Effectiveness of Rosuvastatin in Treating Patients to Low-Density Lipoprotein Cholesterol Goals Compared With Atorvastatin, Pravastatin, and Simvastatin (a US Analysis of the STELLAR Trial)The American Journal of Cardiology, 2005
- Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinenceWomen's Health Issues, 2003
- Direct Medical Costs of Coronary Artery Disease in the United StatesThe American Journal of Cardiology, 1998
- Lifetime Cost of Stroke in the United StatesStroke, 1996
- Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.Stroke, 1993
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983